Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immunic, Inc. (IMUX : NSDQ)

• Company Description    Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis. The company's product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States. Number of Employees: 92

• Price / Volume Information    Yesterday's Closing Price: $16.50 Daily Weekly Monthly 20 Day Moving Average: 164,815 shares Shares Outstanding: 13.64 (millions) Market Capitalization: $225.13 (millions) Beta: 1.41 52 Week High: $17.43 52 Week Low: $5.06 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 15.55% 11.54% 12 Week 10.22% 8.63% Year To Date 209.16% 170.26%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1200 AVENUE OF THE AMERICAS SUITE 200 - NEW YORK,X1 10036 USA ph: 332-255-9818 fax: 858-673-6843 jessica.breu@imux.com http://www.imux.com

• General Corporate Information    Officers Daniel Vitt - Chief Executive Officer;Director; Simona Skerjanec - Chair of the Board of Director Glenn Whaley - Chief Financial Officer Duane D. Nash - Director Tamar Howson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 4525EP200 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/12/26 Share - Related Items Shares Outstanding: 13.64 Most Recent Split Date: 4.00 (0.10:1) Beta: 1.41 Market Capitalization: $225.13 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.89 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.88 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.76 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 60.00% vs. Previous Quarter: 25.93% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - -157.89 03/31/26 - -220.75 12/31/25 - -1,197.81 ROA 06/30/26 - -107.88 03/31/26 - -132.04 12/31/25 - -264.95 Current Ratio 06/30/26 - 5.05 03/31/26 - 4.92 12/31/25 - 0.75 Quick Ratio 06/30/26 - 5.05 03/31/26 - 4.92 12/31/25 - 0.75 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - 9.35 03/31/26 - 11.10 12/31/25 - -0.55 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - - Debt-to-Capital 06/30/26 - 0.00 03/31/26 - 0.00 12/31/25 - -

Powered by Zacks Investment Research ©